CoChat

The DOI matches its Crossref record; 213 of the 214 references it cites were found in a registry or an index.

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Llovet, Josep M., De Baere, Thierry, Kulik, Laura, Haber, Philipp K., Greten, Tim F., Meyer, Tim, Lencioni, Riccardo · 2021 · Nature Reviews Gastroenterology & Hepatology

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided liver tumour-directed procedures, play a leading part in the management of 50-60% of HCCs. Radiofrequency is the mainstay for local ablation at early stages and transarterial chemoembolization (TACE) remains the standard treatment for intermediate-stage HCC. Other local ablative techniques (microwave ablation, cryoablation and irreversible electroporation) or locoregional therapies (for example, radioembolization and sterotactic body radiation therapy) have been explored, but have not yet modified the standard therapies established decades ago. This understanding is currently changing, and several drugs have been approved for the management of advanced HCC. Molecular therapies dominate the adjuvant trials after curative therapies and combination strategies with TACE for intermediate stages. The rationale for these combinations is sound. Local therapies induce antigen and proinflammatory cytokine release, whereas VEGF inhibitors and tyrosine kinase inhibitors boost immunity and prime tumours for checkpoint inhibition. In this Review, we analyse data from randomized and uncontrolled studies reported with ablative and locoregional techniques and examine the expected effects of combinations with systemic treatments. We also discuss trial design and benchmarks to be used as a reference for future investi…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41575-020-00395-0

Cites

213 of 213 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 213 references

Cited by

See all 1,044

Metadata

Authors
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R.
Affiliations
  • Institució Catalana de Recerca i Estudis Avançats (ES)
  • Northwestern University (US)
  • Tisch Cancer Institute (US)
  • National Institutes of Health (US)
  • The Royal Free Hospital (GB)
  • University of Pisa (IT)
Corresponding author
Llovet, Josep M.
Venue
Nature Reviews Gastroenterology & Hepatology
Published
2021-01-28
Volume
18
Issue
5
Pages
293-313
ISSN
  • 1759-5045 (ISSN-L)
  • 1759-5053
OpenAlex
W3121807241
Cited by
1,044
References
214
Citations by year
2026: 158 · 2025: 219 · 2024: 225 · 2023: 209 · 2022: 183 · 2021: 49
FWCI
21.73
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Gastroenterology & Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Funders
  • Cancer Research UK (C9380/A268-13, 26813)
  • National Institute for Health and Care Research
  • National Cancer Institute (P30CA196521)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
hepatocellular carcinoma, locoregional therapy, transarterial chemoembolization, radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation, radioembolization, stereotactic body radiotherapy, VEGF inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, combination therapy, tumor immunogenicity, adjuvant therapy
MeSH terms
Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Embolization, Therapeutic, Enzyme Inhibitors, Carcinoma, Hepatocellular, Humans, Immunotherapy, Liver Neoplasms, Neoplasm Staging, Research Design, Radiosurgery, Treatment Outcome, Chemotherapy, Adjuvant, Radiotherapy, Adjuvant, Neoadjuvant Therapy, Ablation Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/s41575-020-00395-0
The paper
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021). Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-020-00395-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.